There are a number of cancer centers and physicians throughout New York and New Jersey that treat mesothelioma cancer. The following includes many of the top New York and New Jersey treatment centers and doctors. For a more complete list of physicians and cancer centers, CLICK HERE to contact one of our health consultants to learn more.

Mesothelioma Cancer Centers in New York

Memorial Sloan Kettering Cancer Center
1275 York Avenue 
New York, NY 10021

New York University Medical Center
530 First Avenue 
New York, NY 10016

New York University Ruttenberg Treatment Center
1470 Madison Ave
New York, NY 10029

Presbyterian Hospital Columbia University
161 Fort Washington Ave 
New York, NY 10032

Roswell Park Cancer Institute
Elm St 
Buffalo, NY 14263

Mount Sinai Hospital
1470 Madison Avenue
New York, NY 10029

New York Mesothelioma Doctors

Tracey Weigel M.D.
Chief of Thoracic Surgery
Westchester Medical Center
100 Woods Road
Valhalla, NY 10595
Thoracic surgeon Dr. Tracey Weigel has been a firm believer in the multidisciplinary approach to treating malignant pleural mesothelioma for many years.Weigel brought that commitment to the Westchester Medical Center Health Network in Valhalla, New York, early in 2017, when she accepted the position as chief of thoracic surgery. She now oversees all thoracic surgery functions at the Westchester Medical Center (WMC), along with those at the nearby Maria Fareri Children’s Hospital, the MidHudson Regional Hospital and the Health Alliance Hospital. Despite her management role, Weigel also will continue seeing pleural mesothelioma patients, performing extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) surgeries. More than anyone, she believes in the importance of chemotherapy and radiation as part of the treatment regimen.
Mesothelioma truly represents a disease that needs to be addressed in a multidisciplinary fashion,” Weigel said. “I advise patients to talk with all three oncologists, a medical, radiation and surgical oncologist, all at once to ensure that all options are clearly explained up front, prior to treatment.”
She understands that communicating with the entire multidisciplinary team can help patients feel more at ease about their treatment and their stay at the hospital. Weigel believes this type of team approach to treatment provides patients with much better care and an improved chance at long-term survival.

Sloan Kettering Physicians

Manjit Bains, M.D., F.A.C.S
(212) 639-7450
Hours: Monday-Friday 9 to 5
Dr. Bains is a thoracic surgeon at the Memorial Sloan-Kettering Cancer Center in New York City. His clinical expertise includes the following: thoracic surgical oncology, lung cancer, esophageal cancer, mediastinal tumors, mesothelioma, pulmonary metastases, video-assisted thoracic surgery, pulmonary and upper gastrointestinal endoscopy, including laser endoscopy, and tracheobronchial and esophageal stents.

David Ilson, M.D.
(646) 497-9053 (New Patients)
(646) 888-4183
Dr. Ilson specializes in gastrointestinal oncology at Memorial Sloan-Kettering Cancer Center in New York City. His clinical expertise includes colorectal, esophageal, pancreatic, gastric, and other gastrointestinal cancers, as well as mesothelioma.

Garrett Nash, M.D.
(646) 497-9065 (New Patients)
Dr. Nash is a surgeon with specialized training in cancers of the colon, rectum, anus, appendix, and peritoneum. The focuses of his practice include minimally invasive techniques for colorectal cancer (including laparoscopy, single-incision laparoscopy, and robotic surgery), avoiding colostomy while preserving bowel, bladder, and sexual function, and the management of peritoneal surface malignancies (including pseudomyxoma peritonei and mesothelioma).

Valerie Rusch, M.D., F.A.C.S
(212) 639-5873
(646) 497-9163
Hours: Monday-Friday 9-5
Dr. Rusch specializes in treating patients with cancers of the lung, esophagus, mediastinum, and chest wall, including those with mesothelioma. Her research interests include the genetics of lung cancer and mesothelioma and predicting how a patient will respond to a particular treatment. She is also involved in developing methods for early detection of thoracic cancers.

Andrea Cercek, M.D.
Dr. Cercek is a board-certified medical oncologist who specializes in the treatment of patients with gastrointestinal cancers, particularly colorectal and appendix cancer, and those with peritoneal mesothelioma. She specializes in both systemic chemotherapy and regional chemotherapy given directly into the liver or the peritoneal cavity. Her research focus is on the development of new therapies for patients, including molecular-based therapies to improve the outcomes for patients with metastatic disease.

Samuel Singer, M.D., F.A.C.S.
Surgical Oncologist Chief, Gastric and Mixed Tumor Service; Vincent Astor Chair of Clinical Research
646 497-9072
Dr. Singer is a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma.  He has extensive experience with this group of cancers, and is one of just a few surgeons in the world focused solely on treating sarcoma patients. His years of experience have enabled him to devise surgical techniques that improve the ability to completely remove these tumors.  In addition to Dr. Singer’s clinical sarcoma practice, he conducts laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. He leads both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.

Prasad Adusumilli, M.D., F.A.C.S.
Deputy Chief, Thoracic Service; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center
646-497-9163 (New Patients)
Dr. Adusumilli is a thoracic surgeon with expertise in the diagnosis and treatment of cancers in the chest — lung cancer, esophageal cancer, mesothelioma, thymoma, mediastinal and chest wall tumors, and cancers metastatic to lung and pleura.  His clinical interests include systematic workup of lung nodules for early diagnosis of lung cancer, accurate staging of thoracic cancers by endoscopic methods such as endobronchial ultrasound (EBUS), and video-assisted thorascopic surgery (VATS).  He takes pride in effective communication with patients, family members, and their primary care physicians by constant and direct access.  He performs minimally invasive, robotic, and open surgical procedures with a focus on patient-oriented outcomes (cancer control, quality of life).
Dr. Adusumilli is involved in clinical research, and is currently the co-Principal Investigator on two trials at Memorial Sloan Kettering:  Protocol 11-037 and Protocol 11-192.
His laboratory research is focused on the development of biomarkers (blood tests) for early detection of cancer and gene therapy for thoracic cancers. These therapies include immunotherapy (enhancing patients’ own immune systems using genetic and cell engineering) and oncolytic viral therapy (killing cancer cells using genetically engineered viruses).

Andreas Rimner, M.D.
Radiation Oncologist
Dr. Rimner is a radiation oncologist who specializes in caring for people with cancers of the chest, known as thoracic cancers. These include lung cancers, pleural mesotheliomas, and thymomas.  He works closely with a highly skilled team of experts from many areas — including surgeons, medical oncologists, radiologists, medical physicists, and radiation therapists — to determine the best treatment options for my patients.  He uses advanced techniques including intensity-modulated radiation therapy and image-guided radiation therapy to precisely target cancers while limiting damage to normal tissues. Dr. Rimner sees nearly 400 patients each year at Memorial Sloan Kettering’s Manhattan facilities.

Marjorie Zauderer, M.D., M.S., F.A.C.P.
Medical Oncologist, Co-Director, MSK Mesothelioma Program
866-675-5864 (New Patients)
Dr. Zauderer is a board-certified medical oncologist who specializes in caring for people with thoracic cancers and she is Co-Director of MSK’s Mesothelioma Program.  She provides personalized care to her patients throughout their treatment.  Care plans are based not only on the type of cancer and its genetics but also on the priorities of each and every patient and family. Dr. Zauderer works closely with my colleagues from other disciplines such as thoracic surgery, radiation oncology, pulmonology, pathology, radiology, and interventional radiology to determine the optimal plan and whether there is an appropriate clinical trial.

NYU Physicians

Harvey I. Pass, M.D.
(212) 263-7300
Dr. Harvey Pass is the director of the New York University Medical Center Division of Thoracic Surgery and is Chief of Thoracic Oncology.  Dr. Harvey Pass is a Phi Beta Kappa graduate of the Johns Hopkins University and Duke Medical School. After completing his cardiothoracic training at the Medical University of South Carolina and a year as a cardiac surgery attending physician, he devoted his career to treating thoracic malignancies including lung cancer, pulmonary metastases, esophageal cancer, and mesothelioma.  He is one of the world’s leading authorities on mesothelioma.

Daniel H. Sterman M.D.
Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine, Department of Medicine
Professor, Department of Cardiothoracic Surgery
Director Multidiciplinary Pulmonary Oncology Prog
Director Division Pulmonary Critical Care Medicine & Sleep Medicine
Dr. Sterman was an Associate Professor of Medicine and Associate Professor in Surgery in the Pulmonary Division at the University of Pennsylvania before coming to NYU. He was the Director of the University of Pennsylvania’s Interventional Pulmonology Program and Clinical Director of Thoracic Oncology Gene Therapy Program of the Center for Lung Cancer and Related Disorders.  In his current role at NYU, his clinical focus relates to thoracic malignancies in relationship with molecular medicine, and advancing technologies in Interventional Pulmonology. His research interests include gene therapy and vaccine therapy for lung cancer, along with therapies for pleural malignancies including mesothelioma.
Dr. Sterman, currently is involved in a series of clinical trials aimed at understanding whether genetic immunotherapy is a viable treatment option for mesothelioma, pleural disease and other thoracic conditions.

Daniel M. Labow M.D.
Associate Professor of Surgery
Known for preforming the HIPEC
New York University Ruttenberg Treatment Center
1470 Madison Ave.
3rd Floor
New York, NY 10029

Roman Perez-Soler M.D.
Chairman of the Department of Oncology
111 East 210th St.
Room 100
Bronx, NY 10467

Robert N. Taub M.D.
Oncologist, pleural mesothelioma
Presbyterian Hospital Columbia U.
161 Fort Washington Ave.
New York, NY 10032

Sai Yendamuri M.D.
Attending Surgeon, Department of Thoracic Surgery
Associate Professor of Oncology
Roswell Park Cancer Institute
Elm St.
Buffalo, NY 14263

Jessica Donington
Associate Director of Thoracic Surgery


Mount Sinai Hospital Physicians

Raja M. Flores, M.D
Mount Sinai School of Medicine
1440 Madison Ave
New York, NY 10029-6574
(212) 241-9466
Dr. Flores is considered a leading expert in the research and treatment of pleural mesothelioma.  Currently Chief of Thoracic Surgery at the Mount Sinai Medical Center, Dr. Flores is a graduate of New York University and Albert Einstein College of Medicine.  He completed numerous internships and residencies including a Thoracic Oncology Clinical Research Fellowship and residency in cardiothoracic surgery at Brigham and Women’s Hospital in Boston.

Andrea Wolf, M.D.
Assistant Professor
Division of Thoracic Surgery at Mount Sinai Medical Center
1190 Fifth Avenue
Box 1028
New York, NY 10029
She graduated Cum Laude from Princeton University and earned highest honors and her medical degree at Harvard Medical School. She trained in General Surgery and served as Chief Resident at Massachusetts General Hospital in Boston. She earned a Masters in Public Health (MPH) in the area of Clinical Effectiveness at Harvard University School of Public Health while researching malignant pleural mesothelioma and early stage lung cancer as a Thoracic Oncology Research Fellow at Brigham and Women’s Hospital, also in Boston.  She has recently completed her training in Cardiothoracic Surgery after serving as Chief Resident in Thoracic Surgery at Brigham and Women’s Hospital.
Dr. Wolf is Director of the new Women’s Lung Cancer Program, which will focus on multidisciplinary treatment, community outreach, education, and clinical research in lung cancer in women.

Kenneth Rosenweig M.D.
Professor and System Chair Radiation Oncology
1184 Fifth Ave. 1st floor.
Box 1236
New York, NY 10029
Dr. Kenneth Rosenzweig is Professor and Chairman of the Department of Radiation Oncology at Mount Sinai School of Medicine in New York. Previously, he spent 13 years at Memorial Sloan-Kettering Cancer Center. He specializes in the treatment of thoracic malignancies, specifically lung cancer and mesothelioma, with radiation therapy.
The focus of his work has been on incorporating new technology into radiation therapy treatment for these diseases. He has specifically worked on implementing and evaluating novel techniques such as intensity modulated radiation therapy, stereotactic body radiotherapy, deep inspiration breath hold, gated radiation therapy and the incorporation of PET scans into the radiation therapy treatment planning process. He was also the principal investigator of a dose escalation study that established the maximum tolerated dose of radiation therapy that can be safely delivered with radiation therapy. He has published over 70 articles in scientific journals on his work and has authored numerous textbook chapters. He has presented his research at numerous national and international scientific meetings.
Dr. Rosenzweig has served on many committees including the Radiation Therapy Oncology Group (RTOG) Lung Committee, the RTOG Data Monitoring Committee, and the National Cancer Institute Clinical Trials Evaluation Panel. He has served as a Consultant to the International Atomic Energy Association. He attended Yale University School of Medicine and did his residency at the Joint Center for Radiation Therapy at Harvard Medical School.

Daniel M Labow, M.D.
Associate Professor of Surgery
Mount Sinai Hospital
1470 Madison Avenue
3rd Floor
New York, NY 10029
Daniel M. Labow, M.D., Chief of the Surgical Oncology Division at Mount Sinai Hospital, is a board-certified Surgeon with a specialty in Surgical Oncology. He has established himself at Mount Sinai Hospital since 2004 after studying medicine at a unique, combined medical school, the Dartmouth-Brown Medical Program, completing his General Surgery residency at the University of Chicago, and receiving his fellowship training at Memorial Sloan-Kettering Cancer Center. As Vice Chair of Outpatient Services for the Department of Surgery, Dr. Labow continuously designs processes to facilitate unprecedented patient care.  Furthermore he instills this practice on the new generation of physicians while working tirelessly to advance the educational program at Mount Sinai Hospital by being the Program Director of Surgical Oncology Fellowship.
During the length of his trainings, as well as 2 additional years post residency, Dr. Labow pursued extensive clinical and basic science research. His clinical and research interests include the diagnosis and treatment of a broad range of both primary and metastatic malignancies including gastric and esophageal cancer, pancreatic neoplasms, primary and metastatic liver malignancies, biliary tract disease, colon and rectal cancer, sarcoma, and melanoma.  Dr. Labow’s devotion to research and training allow him to understand the entire spectrum of treatments for these cancers, including investigational approaches to help guide each individual patient along the appropriate treatment unique pathway. Moreover, he concentrates in the application of minimally invasive techniques and their role in cancer care.
At Mount Sinai Hospital, Dr. Labow established and directs one of the busiest Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) programs in the country. This technique, which combines surgery with chemotherapy, has revolutionized the treatment of cancers in the abdominal (peritoneal) lining that stem from colon, gastric, ovarian, and appendiceal cancers, as well as mesothelioma and pseudomyxoma peritonei. HIPEC is essentially a chemotherapy "bath" that delivers heated chemotherapy directly into the abdominal cavity, where it penetrates the diseased tissue directly. This targeted contact of the heated drug kills the tumor nodules, which increases absorption of the chemotherapy solution. Dr. Labow, who has performed more than 220 HIPEC procedures since 2007, recognizes the vitality the combination procedure has in significantly extending patient survival rates whilst minimizing the known side effects of chemotherapy that are normally administered intravenously. Additionally, it destroys undetected cancer cells after the tumor has been removed, preventing them from forming into new tumors and causing a reoccurrence of cancer.

Mesothelioma Cancer Centers in New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Street 
New Brunswick, NJ 08903

John Theurer Cancer Center
92 Second Street 
Hackensack, NJ 07601

New Jersey Mesothelioma Doctors

Richard Alexander M.D.
Chief Surgical Officer, Professor of Surgery
Specialty: Surgical Oncology
Rutgers Cancer Institute of New Jersey
195 Little Albany St.
New Brunswick, NJ 08903
Dr. H. Richard Alexander is a world-renowned surgical oncologist and cancer researcher. He has a special interest in abdominal cancers, including peritoneal mesothelioma.
Alexander joined Rutgers in 2017 after serving as head of surgical oncology at the University of Maryland School of Medicine and Greenebaum Cancer Center.
In his clinical practice, Alexander offers innovative treatment options for various cancers that are difficult to treat. He developed an interest in peritoneal mesothelioma early in his career and has since made numerous breakthroughs on the nature of the disease and, more importantly, how mesothelioma doctors can treat it most effectively.

Joseph Aisner, M.D.
Co-Director, Thoracic Oncology Program
Medical Oncologist
Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903
(732) 235-2465
He has been in oncology practice for over 40 years, the last 18 of which have been at the Cancer Institute of New Jersey.
Since even before training as a fellow at the National Cancer Institute, which was preceded by a residency at Georgetown University Hospital, he has had a strong interest in oncology. His long-standing research has focused on clinical trials and the application of evidence based medical practice.
To schedule a new patient appointment call 732-235-8515.

Todd Demmy, M.D., F.A.C.S., F.C.C.P.
Chief, Thoracic Oncology
Associate Chief Surgical Officer
Chief, Thoracic Surgery, Division of Cardiothoracic Surgery
Professor of Surgery
Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903
Following completion of his medical degree from Jefferson Medical College, Dr. Demmy completed a general surgery internship at Baylor College of Medicine followed by a residency and research fellowship in cardiothoracic and cardiovascular surgery at Allegheny General Hospital-West Campus, Medical College of Pennsylvania.
By achieving a very high reliability in performing minimally invasive operations for even complex tumors and by communicating these enabling techniques to other surgeons by annotated video productions, Dr. Demmy has been rewarded with national and international recognition.  His primary research interest, besides studying the outcome of advanced VATS techniques, focuses on the use of regional lung chemotherapeutics.

Harry D. Harper, M.D.
Co-chief Thoracic Oncology
John Theurer Cancer Center
92 Second Street
Hackensack, NJ 07601
Hematologist/oncologist Harry D. Harper, M.D., is co-chief of the Division of Thoracic Oncology at John Theurer Cancer Center at Hackensack University Medical Center. Dr. Harper is skilled in treating all thoracic cancers, especially lung cancer, which is the most common type of thoracic cancer seen at John Theurer Cancer Center. His expertise in lung cancer includes treating small cell, non-small cell (epidermoid carcinoma, adenocarcinoma and large cell carcinoma), and pleural mesothelioma. Dr. Harper’s research has been published in several medical journals, including Cancer, the Journal of Clinical Oncology and the Journal of General Virology.
Dr. Harper employs chemotherapy as neoadjuvant treatment, chemotherapy for advanced disease and chemo/radiation therapy as definitive treatment. He is an expert in targeted therapies and personalized medicine for lung cancer.